By Baystreet
The old adage, “he also serves who only sits and waits,” is being severely tested these days with the impatience millions are feeling to see some sort of banishment of the deadly COVID-19.
Thomas Edison’s statement “he also serves who hustles while he waits”, is likely more appropriate. And the plaudits are being directed toward those health-care companies, hustling and making headway on this front.
Health-care concerns pulled ahead of breakeven by 0.4% in U.S. markets, while in Canada, the sector was punished 2.3%.
San Diego-based AXIM Biotechnologies, Inc. (OTC:AXIM), announced Thursday the completion of a study highlighting the performance of NeuCovix, AXIM’s rapid test to measure levels of neutralizing anti-COVID-19 antibodies.
